Project Grant R01AG079283

Award Date 5/15/24
Completion Date 4/30/29
Dollars Obligated $2.2M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $784,596 to Northeastern University to conduct comprehensive proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The goal is to substantially expand understanding of protein dysfunctions in AD by profiling multiple brain regions, disease stages, and subtypes using advanced mass spectrometry methods. The research will also pair...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Wisconsin-Madison will support the development of a new high-throughput assay to measure the formation of amyloid-beta (Aβ) oligomers. The $219,930 award, effective September 15, 2024 through June 30, 2027, will enable the researchers to use a genetically encoded sensor to detect Aβ oligomer formation and convert it into a reporter gene expression. This innovative approach will allow...
This Project Grant award from the National Institute on Aging's Aging Research Program (CFDA 93.866) provides $717,709 to Weill Medical College of Cornell University to conduct research on the cellular mechanisms underlying the propagation of misfolded tau protein aggregates in Alzheimer's disease (AD) and frontotemporal dementia (FTD). The key objectives are to: 1) Determine how amyloid-beta and tau seeding influence tau protein interactomes in human neurons expressing different tau isoforms;...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $328,000 to an interdisciplinary research team at the University of California, San Francisco (UCSF) to conduct a pilot study titled "Alzheimer's Disease Organelle Proteome Task (ADOPT) - Pilot Phase." The project aims to quantitatively measure the organelle proteome, including protein abundance, post-translational modifications, and protein...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,840,883.00 to Emory University to conduct a proteomic comparison of sporadic early-onset, late-onset, and autosomal dominant Alzheimer's disease. The goal is to advance the understanding of the pathophysiology of sporadic early-onset Alzheimer's disease (SEOAD) and how it differs from late-onset Alzheimer's disease (LOAD) and autosomal dominant Alzheimer's disease (ADAD). The project will...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to characterize the biochemical and biological properties of misfolded amyloid-beta (Aβ) in the eyes of Alzheimer's disease (AD) patients, and evaluate the potential for eye-derived misfolded Aβ to seed pathological aggregation in mouse models. The $429,000 award to the University of Texas Health Science Center at Houston will fund this two-year study, which aims to provide initial...
This $1,623,119 project grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research characterizing Alzheimer's amyloid-beta oligomer structures through May 2025. The grantee, Georgia Tech Research Corporation, will use solid-state nuclear magnetic resonance and cryo-electron microscopy to achieve high-resolution structural characterization of a unique 150 kDa amyloid-beta oligomer. Researchers will obtain a...
This $200,323 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research by the University of South Florida to investigate the aggregation of amyloid-beta (Aβ) peptides during metabolic stress and spreading depolarization events in the brain. The project will utilize multiscale modeling, high-resolution microscopy, antibody staining, and paralysis phenotype testing in C. elegans to determine how physiochemical changes...
This $780,644 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) aims to investigate the relationship between protein phase separation, aggregation, and the age-dependency of human diseases. The research will leverage comprehensive libraries of disease-associated protein mutations to define how phase separation and aggregation processes contribute to the onset and progression of age-related diseases. Key objectives include: Defining the phase...

MASS SPECTROMETRY-BASED PROTEIN FOOTPRINTING: A NEW TOOL FOR AMYLOID PROTEIN AGGREGATION - THE "AMYLOID HYPOTHESIS" POSITS THAT AMYLOID (A) MISFOLDS, OLIGOMERIZES TO SOLUBLE SPECIES, AND THEREBY CONTRIBUTES TO NEURODEGENERATIVE ALZHEIMER'S DISEASE (AD). RECENT SUPPORT FOR THE HYPOTHESIS COMES FROM A NEW ANTIBODY, LECANEMAB, THAT TARGETS A AND ITS AGGREGATION AND SIGNIFICANTLY REDUCES CLINICAL DECLINE. STILL, THE AGGREGATION IS NOT UNDERSTOOD, LEAVING A WEAK FOUNDATION FOR BUILDING NEW THERAPEUTICS. IN THE TRANSITION FROM MONOMER TO FIBRIL, A EXISTS IN SOLUBLE, PUTATIVELY NEUROTOXIC SPECIES IN MIXTURES OF VARIED SIZES AND MORPHOLOGIES. COMPLICATING MATTERS FURTHER IS THE UNKNOWN MOLECULAR ROLE OF APOLIPOPROTEIN E (APOE), A FAMILY OF PARTIALLY DISORDERED PROTEINS INCLUDING AN ISOFORM, APOE4, THAT IS ONE OF FEW BIOMARKERS FOR AD. THE AGGREGATE MIXTURE AND THE INTERACTIONS OF A WITH APOE4 AND WITH LIPIDS CONSTITUTING CELL MEMBRANES ARE TOO COMPLEX FOR MANY STRUCTURAL CHARACTERIZATION TECHNIQUES. PROTEIN FOOTPRINTING COUPLED WITH MASS SPECTROMETRY, HOWEVER, CAN PROVIDE A MEASURE OF SOLVENT ACCESSIBILITY, LOCAL DYNAMICS AND STRUCTURE, HYDROGEN BONDING, SITES OF LIGAND- BINDING, AND OLIGOMERIZATION, WITH SPATIAL RESOLUTION AT THE PEPTIDE AND AMINO-ACID RESIDUE LEVELS. CONSIDERABLE PRELIMINARY DATA ESTABLISH THAT THIS TECHNIQUE CAN PROVIDE STRUCTURAL DETAILS NOT OBTAINABLE BY OTHER METHODS. THIS FOOTPRINTING TECHNIQUE HAS NOT YET BEEN SYSTEMATICALLY OR RIGOROUSLY APPLIED TO CHARACTERIZE THE SOLUBLE INTERMEDIATES FORMED IN AMYLOIDOGENIC PROTEIN AGGREGATION, AND THIS IS OUR GOAL. WE WILL CHEMICALLY FOOTPRINT A AND APOE ALONE OR TOGETHER BY USING BOTH PULSED HYDROGEN/DEUTERIUM EXCHANGE (HDX) AND IRREVERSIBLE MODIFICATION BY HIGHLY REACTIVE SPECIES (FREE RADICALS, CARBENES, CARBOCATIONS). FOR THE LATTER, WE WILL UTILIZE THE "FAST PHOTOCHEMICAL OXIDATION OF PROTEINS" OR "FPOP" PLATFORM, WHICH WE INVENTED. BOTH HDX AND FPOP ARE USED IN A DIFFERENTIAL MODE WHERE CHANGES IN STRUCTURE ARE DETERMINED AS A FUNCTION OF AGGREGATION TIME OR INCREASING MEDIA COMPLEXITY. UTILIZATION OF OPTIMIZED REAGENTS WILL BE COUPLED WITH SEPARATION AND KINETIC MODELING TO REDUCE HETEROGENEITY AND ANALYZE THE AGGREGATION PATHWAYS AND THE VARIED STRUCTURES OR MORPHOLOGIES OF THE OLIGOMERS. WE WILL THEN APPLY THESE OPTIMIZED FOOTPRINTING APPROACHES IN COMPLEX MEDIA CONTAINING LIPIDS, SMALL MOLECULES, AND OTHER PROTEINS INCLUDING ANTIBODIES TO REVEAL HOW AGGREGATION CHANGES UPON PERTURBATION WITH THESE SUBSTANCES. WE WILL BE GUIDED BY POWERFUL DENSITY FUNCTIONAL THEORY THAT CAN PROBE SMALL MOLECULE/A INTERACTIONS ONCE THE FOOTPRINTING AND DATA PROCESSING PASS RIGOROUS VALIDATION, WE WILL APPLY THEM TO A AND APOE IN A SYSTEM OF REPROGRAMMED NEURONS THAT RECAPITULATE THE PATHOPHYSIOLOGY OF AD PATIENTS. THIS SYSTEM SUCCEEDS WHERE PLURIPOTENT STEM CELLS AND MOUSE MODELS DO NOT BECAUSE THEY DON'T CARRY AGE INFORMATION, AND AGE CORRELATES STRONGLY WITH AD. THE PROPOSED RESEARCH WILL BRING NEW UNDERSTANDING OF A AGGREGATION AND OF APOE INTERACTIONS WITH REGIONAL AND AMINO ACID RESOLUTION IN RELEVANT MEDIA. IT WILL ALSO DEFINE AND CHARACTERIZE A NOVEL AND POTENTIALLY INFORMATIVE APPROACH FOR GAINING INSIGHT ON NEURODEGENERATIVE DISEASES.

Posted 5/10/24, 12:00 AM